Navigation Links
Sinobiopharma Secures Rights to Seven Key Patents
Date:4/27/2009

NANJING, China, April 27 /PRNewswire-FirstCall/ -- Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: SNBP) is pleased to announce that it has secured rights to seven key patents from Company CEO Dr. Lequn Huang and the patents' co-holders. The patents that will significantly enhance Sinobiopharma's ability to execute on its mission of bringing safe, low-cost, high-efficacy biopharmaceuticals to market.

The patents are for the following:

  1. Synthesis of amantadine hydrochloride
  2. Method for preparation of 17-acylsinomenine derivatives
  3. Preparation of 17-sulfonylsinomenine
  4. Preparation of N-substituted sinomenine
  5. Method for preparation of Sinomenine compound having dextro-rotary C ring-deficient morphinan skeleton
  6. Synthesis of Eplerenone from 11 -hydroxycanrenone
  7. Method for resolving tetrahydroisoquinoline racemate

Sinobiopharma will be applying these patents as well as using its own innovative applications of them in new drug development.

About Sinobiopharma

Sinobiopharma Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
2. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
3. Sinobiopharma, Inc. Appoints New Director of Marketing
4. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
5. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
6. Aerovance Secures $38 Million in Equity Financing
7. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
8. Pearl Therapeutics Secures $8 Million in Debt Financing
9. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
10. Sopherion Therapeutics Secures $55 Million in Series C Funding
11. Northwest Biotherapeutics Secures $700,000 Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Alex,s Lemonade ... announced that that it will open a state-of-the-art bioinformatics ... childhood cancer research. This announcement comes as Liz ... attends the National Cancer Moonshot Summit in ... Dr. Biden as a participant and advocate of pediatric ...
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
Breaking Biology News(10 mins):